Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 1998

View Archived Issues

FK-506: a topical agent for the treatment of moderate to severe atopic dermatitis

Photogen announces results from animal studies on activation process of photodynamic agents

PPL reports expression of FIX at high concentrations in milk of transgenic sheep

New antiasthmatic agents claimed by Byk Gulden

Life Medical Sciences receives FDA approval to begin Repel-CV trials

Method of detecting HAV infection available for licensing from NIH

Progenitor, CAT establish gene-to-clinic collaboration

Isis and Zeneca collaborate on oligonucleotide manufacturing; fomivirsen filing in sight

Coulter completes patient enrollment in Bexxar phase III trial

PathoGenesis seeks Canadian approval for TOBI in CF

CTL establishes antigen discovery collaboration with University of Tubingen

Compounds with high binding affinity for the 5-HT7 receptor described by Meiji Seika

New antitumor agents discovered by Toagosei

Antiplatelet agents disclosed by Nippon Steel

Selective factor Xa inhibitors in development at Banyu

Spotlight on dual-action ACE/NEP inhibitors

New agents for PDT reported by Yeda

CytoMed and UCB join forces to develop antiinflammatory therapeutics

Salix Holdings name change

ST-630 successfully completes phase Ia trial for osteoporosis

Hoechst discovers inhibitors of various inflammatory mediators

New retinoid-like compounds discovered at Allergan

NIH will license out new technology for studying bone metabolism

Angiogenesis-inhibitory monokine available for licensing from NIH

Novel treatment for red blood cell disorders available for licensing

Ribozyme, Parke-Davis collaboration confirmed

Synaptic licenses technology for BPH treatment to Glaxo Wellcome

UPMC leads the way in gene therapy for musculoskeletal disorders

UPMC studies feasibility of gene therapy for osteoporosis

Gene therapy for treating growth hormone deficiencies

VEGF gene medicine incorporating DOTMA enters phase II testing

Neurogen describes treatment for stress-related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...